New Screen-to-Lead Data Analysis and Management Platform Genedata Screener 5.5 Released

Basel, Switzerland, 2008/04/03

Genedata, a leading provider of in silico solutions for the pharmaceutical and life sciences industries, today announced the release of Genedata Screener 5.5, its new enterprise solution for high throughput and high content screening analysis.

The Screener platform, currently in use at several large pharmaceutical and biotech companies, combines enterprise-wide assay data management with high-performance processing workflows and flexible analysis tools. Screener rapidly analyzes, integrates and manages all assay data, independent of instrumentation, technology, volume or location. The findings are then combined with chemical, pharmacological and in vivo data to support scientists in the tasks of compound prioritization and identification of quality lead structures with the highest confidence.

Screener 5.5 features easy integration of pharmacological fit models and advanced functionality for analyzing experiments with multiple readouts. Users will greatly benefit from the ability to integrate new fit models that are relevant for their particular workflows, such as the Morrison equation for Ki fitting, or new proprietary and public fit algorithms. In addition, the open and scalable architecture extends Screener’s applicability as enterprise screening analysis platform, from uHTS centers to therapeutic areas, and provides access to a wide range of information in corporate research and drug discovery systems.

Dr. Othmar Pfannes, CEO of Genedata, said, “Already deployed worldwide throughout the pharmaceutical industry, Screener has been described as a catalyst in improving the quality of screening-based team research efforts in global enterprises. We are confident that our Screener 5.5 release will build on this excellent reputation, providing our growing customer base with the ways and means of mastering today`s screen-to-lead challenges.”

About Genedata
Genedata develops and globally markets sophisticated computational solutions for drug discovery and related research processes in the life sciences. Genedata’s solutions enable scientists to process, integrate, analyze, and manage large and complex experimental data sets generated by high throughput technologies. Our solutions include Genedata Phylosopher® for target discovery and integrative biological data management, Genedata Screener® for automated high throughput screening and high content screening, and Genedata Expressionist® for biomarker discovery and personalized medicine. Founded in 1997, Genedata is privately held, with headquarters in Basel, Switzerland, and offices in Boston & San Francisco, USA, Konstanz & Munich, Germany and Tokyo, Japan. For more information, please visit www.genedata.com

Contact
Genedata AG
Allison Kurz
Marketing & Communications
Phone: +41 61 511 8459
communications@genedata.com
www.genedata.com

Disclaimer
The statements in this press release that relate to future plans, events or performance are forward-looking statements that involve risks and uncertainties, including risks associated with uncertainties related to contract cancellations, developing risks, competitive factors, uncertainties pertaining to customer orders, demand for products and services, development of markets for the Company's products and services. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. The Company undertakes no obligation to release publicly the result of any revisions to these forward-looking statements that may be made to reflect events or circumstances after the date hereof or to reflect the occurrence of unanticipated events.